Therapeutic Applications of Micro-RNA in Cancer Management

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Biopharmaceuticals".

Deadline for manuscript submissions: 25 September 2025 | Viewed by 885

Special Issue Editor


E-Mail Website
Guest Editor
Instituto de Salud Pública, Universidad Veracruzana (UV), Xalapa, México
Interests: cancer; ncRNAs; therapeutic applications; cancer epidemiology; biomarkers in cancer

Special Issue Information

Dear Colleagues,

Cancer is a disease characterized by the development of abnormal cells that divide uncontrollably and can infiltrate and destroy tissues. This disease is the second leading cause of death in the world, making it a major public health problem. Conventional cancer treatments such as chemotherapies, immunotherapy and targeted therapies are effective until the cancer becomes resistant to the treatment. Therefore, there must be a window of therapeutic options.

MiRNAs are small non-coding RNA sequences with a length of about 20 nucleotides that regulate gene expression. Their deregulation is associated with cancer, and they even act as oncogenes or tumor suppressor genes, playing an important role in tumor biology. In this sense, restoration of miRNA expression and inhibition of overexpressed miRNAs normalizes their function by reversing tumor cell phenotypes. Therefore, the idea of converting miRNAs into therapeutic agents is gaining relevance in this research field, through the use of synthetic molecules, nanoparticles, vesicles, quatsomes, etc., as vehicles for miRNAs to inhibit proliferation, cancer cell invasion, promote apoptosis, inhibit metastasis and increase sensitivity to treatments. This research is laying the groundwork for the application of miRNAs in cancer treatment.

The journal Pharmaceuticals invites both reviews and original articles that shed light on advances in the therapeutic uses of miRNAs for cancer treatment. The collection of manuscripts will be published as a Special Issue of the journal.

Dr. Alma D. Campos-Parra
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • miRNAs
  • therapeutic applications
  • miRNA treatments

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

25 pages, 1200 KiB  
Review
MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships
by Alma D. Campos-Parra, David Sánchez-Marín and Víctor Acevedo-Sánchez
Pharmaceuticals 2025, 18(4), 492; https://doi.org/10.3390/ph18040492 - 28 Mar 2025
Viewed by 279
Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatments by being less toxic and improving the survival of cancer patients. The greatest challenge to their success is the resistance exhibited by cancer patients. However, the potential of microRNAs (miRNAs) for sensitizing molecules to TKIs [...] Read more.
Tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatments by being less toxic and improving the survival of cancer patients. The greatest challenge to their success is the resistance exhibited by cancer patients. However, the potential of microRNAs (miRNAs) for sensitizing molecules to TKIs has been well recognized, with several reports publishing promising results. Nonetheless, this therapeutic window faces challenges and several often-overlooked limitations. One of the most fundamental challenges is selecting the optimal miRNA candidates for clinical trials, as miRNAs are promiscuous and regulate hundreds of targets. In this review, we describe how miRNAs enhance sensitivity to TKIs across various types of cancer. We highlight several challenges and limitations in achieving a successful collaboration between small molecules (TKIs–miRNAs). Our focus is on proposing a workflow to select the most suitable miRNA candidate, recommending several available bioinformatics tools to develop a successful therapeutic partnership between TKIs and miRNAs. We hope that this initial proposal will provide valuable support for future research. Full article
(This article belongs to the Special Issue Therapeutic Applications of Micro-RNA in Cancer Management)
Show Figures

Graphical abstract

Back to TopTop